| 4.1 All‐cause mortality prior to hospital discharge |
1 |
238 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.75 [0.25, 2.30] |
| 4.2 Failure to extubate within one week of commencing treatment |
2 |
365 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.52 [0.36, 0.74] |
| 4.3 Reintubation within one week of commencing treatment |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 4.4 Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine |
2 |
365 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.86 [0.68, 5.09] |
| 4.5 Bronchopulmonary dysplasia/chronic lung disease: 28 days of oxygen exposure |
1 |
238 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.84 [0.68, 1.04] |
| 4.6 Bronchopulmonary dysplasia/chronic lung disease at 36 weeks' postmenstrual age |
1 |
238 |
Risk Difference (M‐H, Fixed, 95% CI) |
‐0.13 [‐0.25, ‐0.01] |
| 4.7 Number of days using mechanical ventilation |
1 |
127 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.02 [‐0.89, 0.85] |
| 4.8 Intraventricular hemorrhage, any grade |
1 |
238 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.02 [0.68, 1.53] |
| 4.9 Intraventricular hemorrhage, grade 3 to 4 |
2 |
365 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.08 [0.74, 22.55] |
| 4.10 Necrotizing enterocolitis (proven = Bell stage of 2 or greater) (Bell 1978) |
2 |
365 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.38 [0.08, 1.79] |
| 4.11 Patent ductus arteriosus (PDA) requiring treatment (cyclo‐oxygenase inhibitors or surgical ligation) |
1 |
127 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.65 [0.30, 1.41] |
| 4.12 Retinopathy of prematurity (ROP) (any ROP) (International Committee 2005) |
1 |
238 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.65 [0.40, 1.05] |
| 4.13 Retinopathy of prematurity (ROP) (severe ROP [stage 3 or greater]) (International Committee 2005) |
1 |
238 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.39 [0.11, 1.45] |
